Lannett Company (NYSE:LCI) spotted trading -30.67% off 52-week high price. On the other end, the stock has been noted 223.12% away from the low price over the last 52-weeks. The stock changed -3.93% to recent value of $10.76. The stock transacted 1353432 shares during most recent day however it has an average volume of 2265.47K shares. The company has 40.44M of outstanding shares and 30.8M shares were floated in the market.
On Oct. 1, 2019, Lannett Company (NYSE:LCI) disclosed that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone Propionate – Salmeterol Xinafoate Powder Inhaler) of Respirent Pharmaceuticals Co. Ltd. ADVAIR DISKUS had U.S. sales of $3.6 billion for the 12 months ending July, 2019, according to IQVIA, although actual generic market values are expected to be lower.
Under the agreement, Lannett will commence U.S. distribution of the product after FDA approval. Lannett will make an upfront payment, as well as future milestone payments, and receive a portion of the net profits once it commences distribution of the product. The term of the agreement is 10 years, which begins upon commencement of distribution. Other terms were not disclosed.
We are pleased to establish a strategic alliance with Respirent, a respiratory focused company developing dry powder inhaled respiratory pharmaceutical products, said Tim Crew, chief executive officer of Lannett. Moreover, Respirent has substantial capabilities around inhalation products and the distinction of being one of the few companies that have progressed generic ADVAIR DISKUS through the clinical stage. We are working with the Respirent team to complete the product filing, which we expect to submit to the FDA in the second half of our current fiscal year.
Generic ADVAIR DISKUS represents a potentially large market opportunity, especially for a company of our size. Over the last 18 months, our strategy for in-licensing products has been focused on near-term opportunities; more recently, we have begun layering in products that have the potential to drive substantial growth to our business over the medium term and beyond.
Its earnings per share (EPS) expected to touch remained -839.10% for this year while earning per share for the next 5-years is expected to reach at 15.00%. LCI has a gross margin of 37.20% and an operating margin of -40.10% while its profit margin remained -41.50% for the last 12 months.
According to the most recent quarter its current ratio was 2.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of -15.11% from the mean of 20 days, 16.48% from mean of 50 days SMA and performed 42.69% from mean of 200 days price. Company’s performance for the week was -22.59%, 4.47% for month and YTD performance remained 116.94%.